Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Medisafe Announces New Adherence Solution for Pharma

By Andrew Berg | July 25, 2016

Medisafe, a provider of medication management platform with three million patient and caregiver registered users, announced today the official launch of Medisafe for Pharma. 

Following a series of successful pilots and engagements over the past year and a half, Medisafe has now bundled a number of services into a software license that helps pharmaceutical companies increase adherence to their medications while gaining actionable de-identified insights generated by self-learning algorithms analyzing billions of user engagement data points Medisafe has collected to date.

Medisafe’s pharma offering simultaneously addresses all three major challenges attributed to non-adherence – patient quality of care (e.g. higher emergency and mortality rates), healthcare system costs (e.g. higher hospitalization rates) and lost revenues (e.g. fewer prescription refills). Pharma and pharmacies share the burden of lost revenues, estimated at $188 billion annually in the U.S. alone.

Medisafe said in a statement that the new offering significantly improves adherence from industry average rates. Pharmaceutical companies can co-brand and customize the Medisafe interface for their patients, while also targeting and engaging patients with educational content (e.g. videos, articles), patient assistance programs (e.g. copay cards), telecare services and other resources into the Medisafe “feed.”

“Medisafe for Pharma is an essential ‘Beyond the Pill’ initiative for any pharmaceutical or life sciences company looking to increase adherence while engaging and learning from patients in the real world. Medisafe is uniquely positioned to produce high-ROI engagements given the millions invested, experience amassed, and user base established in the three plus years since its launch,” said Jon Michaeli, Medisafe’s EVP of Marketing and Business Development.

Medisafe’s AI-driven personalized user interface (UI) delivers a tailored contextual experience to each user, and the company’s role as an unbiased third party assists patients with all of their medications to improve their health holistically.

Medisafe is a cloud-based platform that personalizes content, resources and interventions based on each user’s regimen, condition and specific circumstance. Medisafe touts nearly three million patient and caregiver users who have recorded over 370 million successful medication doses on their iOS and Android smartphones and tablets.


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE